Anthem Biosciences Limited (NSE:ANTHEM)
India · Delayed Price · Currency is INR 737.95
-20.75 (-2.73%)
At close: Aug 1, 2025, 3:30 PM IST
Anthem Biosciences Revenue
In the fiscal year ending March 31, 2025, Anthem Biosciences had annual revenue of 18.50B INR with 30.29% growth. Anthem Biosciences had revenue of 9.84B in the half year ending March 31, 2025.
Revenue
18.50B
Revenue Growth
+30.29%
P/S Ratio
22.41
Revenue / Employee
9.43M
Employees
1,825
Market Cap
414.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18.50B | 4.30B | 30.29% |
| Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
| Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
| Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
| Mar 31, 2021 | 11.05B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.86B |